Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 275

1.

Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer.

Murthy RK, Loi S, Okines A, Paplomata E, Hamilton E, Hurvitz SA, Lin NU, Borges V, Abramson V, Anders C, Bedard PL, Oliveira M, Jakobsen E, Bachelot T, Shachar SS, Müller V, Braga S, Duhoux FP, Greil R, Cameron D, Carey LA, Curigliano G, Gelmon K, Hortobagyi G, Krop I, Loibl S, Pegram M, Slamon D, Palanca-Wessels MC, Walker L, Feng W, Winer EP.

N Engl J Med. 2019 Dec 11. doi: 10.1056/NEJMoa1914609. [Epub ahead of print]

PMID:
31825569
2.

Cerebrospinal fluid neurofilament light chain is elevated in Niemann-Pick type C compared to psychiatric disorders and healthy controls and may be a marker of treatment response.

Eratne D, Loi SM, Li QX, Varghese S, McGlade A, Collins S, Masters CL, Velakoulis D, Walterfang M.

Aust N Z J Psychiatry. 2019 Dec 11:4867419893431. doi: 10.1177/0004867419893431. [Epub ahead of print] No abstract available.

PMID:
31823653
3.

Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer.

Smyth LM, Piha-Paul SA, Won HH, Schram AM, Saura C, Loi S, Lu J, Shapiro GI, Juric D, Mayer IA, Arteaga CL, de la Fuente MI, Brufksy AM, Spanggaard I, Mau-Sorensen M, Arnedos M, Moreno V, Boni V, Sohn J, Schwartzberg LS, Gonzalez-Farre X, Cervantes A, Bidard FC, Gorelick AN, Lanman RB, Nagy RJ, Ulaner GA, Chandarlapaty S, Jhaveri K, Gavrila EI, Zimel C, Selcuklu SD, Melcer M, Samoila A, Cai Y, Scaltriti M, Mann G, Xu F, Eli LD, Dujka M, Lalani AS, Bryce R, Baselga J, Taylor BS, Solit DB, Meric-Bernstam F, Hyman DM.

Cancer Discov. 2019 Dec 5. pii: CD-19-0966. doi: 10.1158/2159-8290.CD-19-0966. [Epub ahead of print]

PMID:
31806627
4.

Metastatic Breast Cancer: TIL it's too late.

Savas P, Loi S.

Clin Cancer Res. 2019 Dec 2. pii: clincanres.3490.2019. doi: 10.1158/1078-0432.CCR-19-3490. [Epub ahead of print]

PMID:
31792035
5.

Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.

Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Investigators.

Lancet Oncol. 2019 Nov 27. pii: S1470-2045(19)30689-8. doi: 10.1016/S1470-2045(19)30689-8. [Epub ahead of print]

PMID:
31786121
6.

Stereotactic ablative body radiotherapy (SABR) for bone only oligometastatic breast cancer: A prospective clinical trial.

David S, Tan J, Savas P, Bressel M, Kelly D, Foroudi F, Loi S, Siva S.

Breast. 2019 Nov 6;49:55-62. doi: 10.1016/j.breast.2019.10.016. [Epub ahead of print]

7.

STOP-Colitis pilot trial protocol: a prospective, open-label, randomised pilot study to assess two possible routes of faecal microbiota transplant delivery in patients with ulcerative colitis.

Quraishi MNN, Yalchin M, Blackwell C, Segal J, Sharma N, Hawkey P, McCune V, Hart AL, Gaya D, Ives NJ, Magill L, Loi S, Hewitt C, Gerasimidis K, Loman NJ, Hansen R, McMullan C, Mathers J, Quince C, Crees N, Iqbal T.

BMJ Open. 2019 Nov 11;9(11):e030659. doi: 10.1136/bmjopen-2019-030659.

8.

'I know they are not trained in dementia': Addressing the need for specialist dementia training for home care workers.

Polacsek M, Goh A, Malta S, Hallam B, Gahan L, Cooper C, Low LF, Livingston G, Panayiotou A, Loi S, Omori M, Savvas S, Batchelor F, Ames D, Doyle C, Scherer S, Dow B.

Health Soc Care Community. 2019 Oct 23. doi: 10.1111/hsc.12880. [Epub ahead of print]

PMID:
31646701
9.

Macrophage-Derived CXCL9 and CXCL10 Are Required for Antitumor Immune Responses Following Immune Checkpoint Blockade.

House IG, Savas P, Lai J, Chen AXY, Oliver AJ, Teo ZL, Todd KL, Henderson MA, Giuffrida L, Petley EV, Sek K, Mardiana S, Gide TN, Quek C, Scolyer RA, Long GV, Wilmott JS, Loi S, Darcy PK, Beavis PA.

Clin Cancer Res. 2019 Oct 21. doi: 10.1158/1078-0432.CCR-19-1868. [Epub ahead of print]

PMID:
31636098
10.

Lucitanib for the Treatment of HR+/HER2- Metastatic Breast Cancer: Results from the Multicohort Phase II FINESSE Study.

Hui R, Pearson A, Cortes J, Campbell C, Poirot C, Azim HA Jr, Fumagalli D, Lambertini M, Daly F, Arahmani A, Perez-Garcia J, Aftimos P, Bedard PL, Xuereb L, Scheepers ED, Vicente M, Goulioti T, Loibl S, Loi S, Pierrat MJ, Turner NC, Andre F, Curigliano G.

Clin Cancer Res. 2019 Oct 16. doi: 10.1158/1078-0432.CCR-19-1164. [Epub ahead of print]

PMID:
31619444
11.

Around the world and back again.

Loi S.

Nat Med. 2019 Oct;25(10):1466. doi: 10.1038/s41591-019-0578-0.

PMID:
31591582
12.

Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy.

Park JH, Jonas SF, Bataillon G, Criscitiello C, Salgado R, Loi S, Viale G, Lee HJ, Dieci MV, Kim SB, Vincent-Salomon A, Curigliano G, André F, Michiels S.

Ann Oncol. 2019 Sep 30. pii: mdz395. doi: 10.1093/annonc/mdz395. [Epub ahead of print]

PMID:
31566659
13.

Comparison of BEAMing and Droplet Digital PCR for Circulating Tumor DNA Analysis.

O'Leary B, Hrebien S, Beaney M, Fribbens C, Garcia-Murillas I, Jiang J, Li Y, Huang Bartlett C, André F, Loibl S, Loi S, Cristofanilli M, Turner NC.

Clin Chem. 2019 Nov;65(11):1405-1413. doi: 10.1373/clinchem.2019.305805. Epub 2019 Sep 24.

PMID:
31551314
14.

Non-invasive in vivo hyperspectral imaging of the retina for potential biomarker use in Alzheimer's disease.

Hadoux X, Hui F, Lim JKH, Masters CL, Pébay A, Chevalier S, Ha J, Loi S, Fowler CJ, Rowe C, Villemagne VL, Taylor EN, Fluke C, Soucy JP, Lesage F, Sylvestre JP, Rosa-Neto P, Mathotaarachchi S, Gauthier S, Nasreddine ZS, Arbour JD, Rhéaume MA, Beaulieu S, Dirani M, Nguyen CTO, Bui BV, Williamson R, Crowston JG, van Wijngaarden P.

Nat Commun. 2019 Sep 17;10(1):4227. doi: 10.1038/s41467-019-12242-1.

15.

The dawn of robust individualised risk models for dementia.

Burnham SC, Loi SM, Doecke J, Fedyashov V, Dore V, Villemagne VL, Masters CL.

Lancet Neurol. 2019 Nov;18(11):985-987. doi: 10.1016/S1474-4422(19)30353-9. Epub 2019 Sep 13. No abstract available.

PMID:
31526626
16.

Triple-negative breast cancer: recent treatment advances.

Bergin ART, Loi S.

F1000Res. 2019 Aug 2;8. pii: F1000 Faculty Rev-1342. doi: 10.12688/f1000research.18888.1. eCollection 2019. Review.

17.

Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis.

Nagpal A, Redvers RP, Ling X, Ayton S, Fuentes M, Tavancheh E, Diala I, Lalani A, Loi S, David S, Anderson RL, Smith Y, Merino D, Denoyer D, Pouliot N.

Breast Cancer Res. 2019 Aug 13;21(1):94. doi: 10.1186/s13058-019-1177-1.

18.

Identification of an excellent prognosis subset of human papillomavirus-associated oropharyngeal cancer patients by quantification of intratumoral CD103+ immune cell abundance.

Solomon B, Young RJ, Bressel M, Cernelc J, Savas P, Liu H, Urban D, Thai A, Cooper C, Fua T, Neeson P, Loi S, Porceddu SV, Rischin D.

Ann Oncol. 2019 Oct 1;30(10):1638-1646. doi: 10.1093/annonc/mdz271.

PMID:
31400196
19.

Residual disease and immune infiltration as a new surrogate endpoint for TNBC post neoadjuvant chemotherapy.

Luen SL, Salgado R, Loi S.

Oncotarget. 2019 Jul 23;10(45):4612-4614. doi: 10.18632/oncotarget.27081. eCollection 2019 Jul 23. No abstract available.

20.

Efficacy of late line pertuzumab with trastuzumab and chemotherapy in HER2-positive metastatic breast cancer: An Australian case series.

Bergin ART, Luen SJ, Savas P, Boolell V, Cho D, Lynch J, Nott L, Stuart-Harris R, Teo LN, Yap SY, Loi S.

Asia Pac J Clin Oncol. 2019 Dec;15(6):377-382. doi: 10.1111/ajco.13195. Epub 2019 Jul 19.

PMID:
31321873
21.

The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine.

Loi S.

Ann Oncol. 2019 Aug 1;30(8):1183-1184. doi: 10.1093/annonc/mdz201. No abstract available.

PMID:
31287498
22.

A pilot study of the utility of cerebrospinal fluid neurofilament light chain in differentiating neurodegenerative from psychiatric disorders: A 'C-reactive protein' for psychiatrists and neurologists?

Eratne D, Loi SM, Walia N, Farrand S, Li QX, Varghese S, Walterfang M, Evans A, Mocellin R, Dhiman K, Gupta V, Malpas CB, Collins S, Masters CL, Velakoulis D.

Aust N Z J Psychiatry. 2019 Jun 21:4867419857811. doi: 10.1177/0004867419857811. [Epub ahead of print]

PMID:
31220922
23.

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.

Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators.

Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6.

24.

Retraction: The E3-ligase E6AP Represses Breast Cancer Metastasis via Regulation of ECT2-Rho Signaling.

Mansour M, Haupt S, Chan AL, Godde N, Rizzitelli A, Loi S, Caramia F, Deb S, Takano EA, Bishton M, Johnstone C, Monahan B, Levav-Cohen Y, Jiang YH, Yap AS, Fox S, Bernard O, Anderson R, Haupt Y.

Cancer Res. 2019 Jun 1;79(11):3008. doi: 10.1158/0008-5472.CAN-19-1133. No abstract available.

PMID:
31160311
25.

Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial.

Lambertini M, Campbell C, Gelber RD, Viale G, McCullough A, Hilbers F, Korde LA, Werner O, Chumsri S, Jackisch C, Wolff AC, Vaz-Luis I, Ferreira AR, Prat A, Moreno-Aspitia A, Piccart M, Loi S, de Azambuja E.

Breast Cancer Res Treat. 2019 Aug;177(1):103-114. doi: 10.1007/s10549-019-05284-y. Epub 2019 May 27.

PMID:
31134488
26.

ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia.

Farshid G, Bilous M, Morey A, Fox S, Lakhani S, Loi S, Bell R, Spillane A.

Pathology. 2019 Jun;51(4):345-348. doi: 10.1016/j.pathol.2019.02.004. Epub 2019 May 7.

PMID:
31076089
27.

Correction: PIK3CA Genotype and a PIK3CA Mutation-Related Gene Signature and Response to Everolimus and Letrozole in Estrogen Receptor Positive Breast Cancer.

Loi S, Michiels S, Baselga J, Bartlett JMS, Singhal SK, Sabine VS, Sims AH, Sahmoud T, Michael Dixon J, Piccart MJ, Sotiriou C.

PLoS One. 2019 Apr 23;14(4):e0216175. doi: 10.1371/journal.pone.0216175. eCollection 2019.

28.

Neoantigen-directed immune escape in lung cancer evolution.

Rosenthal R, Cadieux EL, Salgado R, Bakir MA, Moore DA, Hiley CT, Lund T, Tanić M, Reading JL, Joshi K, Henry JY, Ghorani E, Wilson GA, Birkbak NJ, Jamal-Hanjani M, Veeriah S, Szallasi Z, Loi S, Hellmann MD, Feber A, Chain B, Herrero J, Quezada SA, Demeulemeester J, Van Loo P, Beck S, McGranahan N, Swanton C; TRACERx consortium.

Nature. 2019 Mar;567(7749):479-485. doi: 10.1038/s41586-019-1032-7. Epub 2019 Mar 20.

PMID:
30894752
29.

Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial.

Rothé F, Silva MJ, Venet D, Campbell C, Bradburry I, Rouas G, de Azambuja E, Maetens M, Fumagalli D, Rodrik-Outmezguine V, Di Cosimo S, Rosa D, Chia S, Wardley A, Ueno T, Janni W, Huober J, Baselga J, Piccart M, Loi S, Sotiriou C, Dawson SJ, Ignatiadis M.

Clin Cancer Res. 2019 Jun 15;25(12):3581-3588. doi: 10.1158/1078-0432.CCR-18-2521. Epub 2019 Mar 12.

PMID:
30862692
30.

Persistent Impairment in Cardiopulmonary Fitness after Breast Cancer Chemotherapy.

Foulkes SJ, Howden EJ, Bigaran A, Janssens K, Antill Y, Loi S, Claus P, Haykowsky MJ, Daly RM, Fraser SF, LA Gerche A.

Med Sci Sports Exerc. 2019 Aug;51(8):1573-1581. doi: 10.1249/MSS.0000000000001970.

PMID:
30829962
31.

Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.

Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, Michiels S, Zhang Z, Giorgetti C, Arnedos M, Huang Bartlett C, Cristofanilli M.

J Clin Oncol. 2019 May 10;37(14):1169-1178. doi: 10.1200/JCO.18.00925. Epub 2019 Feb 26. Erratum in: J Clin Oncol. 2019 Nov 1;37(31):2956.

32.

Correction: RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors.

Loi S, Dushyanthen S, Beavis PA, Salgado R, Denkert C, Savas P, Combs S, Rimm DL, Giltnane JM, Estrada MV, Sánchez V, Sanders ME, Cook RS, Pilkinton MA, Mallal SA, Wang K, Miller VA, Stephens PJ, Yelensky R, Doimi FD, Gómez H, Ryzhov SV, Darcy PK, Arteaga CL, Balko JM.

Clin Cancer Res. 2019 Feb 15;25(4):1437. doi: 10.1158/1078-0432.CCR-18-4264. No abstract available.

PMID:
30770496
33.

Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial.

Loi S, Giobbie-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, Campone M, Biganzoli L, Bonnefoi H, Jerusalem G, Bartsch R, Rabaglio-Poretti M, Kammler R, Maibach R, Smyth MJ, Di Leo A, Colleoni M, Viale G, Regan MM, André F; International Breast Cancer Study Group and the Breast International Group.

Lancet Oncol. 2019 Mar;20(3):371-382. doi: 10.1016/S1470-2045(18)30812-X. Epub 2019 Feb 11.

PMID:
30765258
34.

Author Correction: HER kinase inhibition in patients with HER2- and HER3-mutant cancers.

Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB.

Nature. 2019 Feb;566(7745):E11-E12. doi: 10.1038/s41586-019-0974-0.

PMID:
30755741
35.

Molecular comparison of interval and screen-detected breast cancers.

Cheasley D, Li N, Rowley SM, Elder K, Mann GB, Loi S, Savas P, Goode DL, Kader T, Zethoven M, Semple T, Fox SB, Pang JM, Byrne D, Devereux L, Nickson C, Procopio P, Lee G, Hughes S, Saunders H, Fujihara KM, Kuykhoven K, Connaughton J, James PA, Gorringe KL, Campbell IG.

J Pathol. 2019 Jun;248(2):243-252. doi: 10.1002/path.5251. Epub 2019 Mar 8.

PMID:
30746706
36.

Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers.

Loi S, Drubay D, Adams S, Pruneri G, Francis PA, Lacroix-Triki M, Joensuu H, Dieci MV, Badve S, Demaria S, Gray R, Munzone E, Lemonnier J, Sotiriou C, Piccart MJ, Kellokumpu-Lehtinen PL, Vingiani A, Gray K, Andre F, Denkert C, Salgado R, Michiels S.

J Clin Oncol. 2019 Mar 1;37(7):559-569. doi: 10.1200/JCO.18.01010. Epub 2019 Jan 16.

PMID:
30650045
37.

PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.

Loibl S, Majewski I, Guarneri V, Nekljudova V, Holmes E, Bria E, Denkert C, Schem C, Sotiriou C, Loi S, Untch M, Conte P, Bernards R, Piccart M, von Minckwitz G, Baselga J.

Ann Oncol. 2019 Jul 1;30(7):1180. doi: 10.1093/annonc/mdy536. No abstract available.

PMID:
30624609
38.

Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.

Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L.

Ann Oncol. 2019 Jan 9. doi: 10.1093/annonc/mdy530. [Epub ahead of print] No abstract available.

39.

Prognostic implications of residual disease tumor-infiltrating lymphocytes and residual cancer burden in triple-negative breast cancer patients after neoadjuvant chemotherapy.

Luen SJ, Salgado R, Dieci MV, Vingiani A, Curigliano G, Gould RE, Castaneda C, D'Alfonso T, Sanchez J, Cheng E, Andreopoulou E, Castillo M, Adams S, Demaria S, Symmans WF, Michiels S, Loi S.

Ann Oncol. 2019 Feb 1;30(2):236-242. doi: 10.1093/annonc/mdy547.

PMID:
30590484
40.

Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement.

Johnson DB, Nixon MJ, Wang Y, Wang DY, Castellanos E, Estrada MV, Ericsson-Gonzalez PI, Cote CH, Salgado R, Sanchez V, Dean PT, Opalenik SR, Schreeder DM, Rimm DL, Kim JY, Bordeaux J, Loi S, Horn L, Sanders ME, Ferrell PB Jr, Xu Y, Sosman JA, Davis RS, Balko JM.

JCI Insight. 2018 Dec 20;3(24). pii: 120360. doi: 10.1172/jci.insight.120360.

41.

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study.

Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, Hui R, Curigliano G, Toppmeyer D, O'Shaughnessy J, Loi S, Paluch-Shimon S, Tan AR, Card D, Zhao J, Karantza V, Cortés J.

Ann Oncol. 2019 Mar 1;30(3):397-404. doi: 10.1093/annonc/mdy517.

PMID:
30475950
42.

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.

Adams S, Loi S, Toppmeyer D, Cescon DW, De Laurentiis M, Nanda R, Winer EP, Mukai H, Tamura K, Armstrong A, Liu MC, Iwata H, Ryvo L, Wimberger P, Rugo HS, Tan AR, Jia L, Ding Y, Karantza V, Schmid P.

Ann Oncol. 2019 Mar 1;30(3):405-411. doi: 10.1093/annonc/mdy518.

PMID:
30475947
43.

The impact of ethnicity on efficacy and toxicity of cyclin D kinase 4/6 inhibitors in advanced breast cancer: a meta-analysis.

Lee KWC, Lord S, Finn RS, Lim E, Martin A, Loi S, Lynch J, Friedlander M, Lee CK.

Breast Cancer Res Treat. 2019 Feb;174(1):271-278. doi: 10.1007/s10549-018-5054-x. Epub 2018 Nov 21.

PMID:
30465154
44.

Fine-tuning chemotherapy in the era of dual HER2 targeting.

Loi S.

Lancet Oncol. 2018 Dec;19(12):1551-1554. doi: 10.1016/S1470-2045(18)30661-2. Epub 2018 Nov 6. No abstract available.

PMID:
30413380
45.

Exercise as a diagnostic and therapeutic tool for the prevention of cardiovascular dysfunction in breast cancer patients.

Howden EJ, Bigaran A, Beaudry R, Fraser S, Selig S, Foulkes S, Antill Y, Nightingale S, Loi S, Haykowsky MJ, La Gerche A.

Eur J Prev Cardiol. 2019 Feb;26(3):305-315. doi: 10.1177/2047487318811181. Epub 2018 Oct 30.

PMID:
30376366
46.

Passion for immune checkpoint blockade in triple negative breast cancer: Comment on the IMpassion130 study.

Kok M, Winer EP, Loi S.

Ann Oncol. 2019 Jan 1;30(1):13-16. doi: 10.1093/annonc/mdy473. No abstract available.

PMID:
30351400
47.

Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, Diéras V, Hegg R, Im SA, Shaw Wright G, Henschel V, Molinero L, Chui SY, Funke R, Husain A, Winer EP, Loi S, Emens LA; IMpassion130 Trial Investigators.

N Engl J Med. 2018 Nov 29;379(22):2108-2121. doi: 10.1056/NEJMoa1809615. Epub 2018 Oct 20.

PMID:
30345906
48.

Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer.

Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M.

N Engl J Med. 2018 Nov 15;379(20):1926-1936. doi: 10.1056/NEJMoa1810527. Epub 2018 Oct 20.

PMID:
30345905
49.

Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.

Cristofanilli M, DeMichele A, Giorgetti C, Turner NC, Slamon DJ, Im SA, Masuda N, Verma S, Loi S, Colleoni M, Theall KP, Huang X, Liu Y, Bartlett CH.

Eur J Cancer. 2018 Nov;104:21-31. doi: 10.1016/j.ejca.2018.08.011. Epub 2018 Oct 8.

50.

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).

Cocco E, Javier Carmona F, Razavi P, Won HH, Cai Y, Rossi V, Chan C, Cownie J, Soong J, Toska E, Shifman SG, Sarotto I, Savas P, Wick MJ, Papadopoulos KP, Moriarty A, Cutler RE Jr, Avogadri-Connors F, Lalani AS, Bryce RP, Chandarlapaty S, Hyman DM, Solit DB, Boni V, Loi S, Baselga J, Berger MF, Montemurro F, Scaltriti M.

Sci Signal. 2018 Oct 9;11(551). pii: eaat9773. doi: 10.1126/scisignal.aat9773.

Supplemental Content

Support Center